Ryan & Maniskas, LLP Announces Investigation of LCA-Vision Inc.
WAYNE, Pa., Feb. 18, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of LCA-Vision Inc. ("LCA-Vision" or the "Company") (NASDAQ: LCAV) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to PhotoMedex, Inc. in a transaction valued at approximately $106.4 million.
If you own shares of LCA-Vision and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/lcav. You may also email Mr. Maniskas at email@example.com.
Under the terms of the agreement, public shareholders of LCA-Vision will receive $5.37 per share in cash for each share of LCA-Vision they own.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by LCA-Vision's Board of Directors for not acting in the Company's shareholders' best interests in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide. To learn more about the class action process, please visit: www.rmclasslaw.com.
SOURCE Ryan & Maniskas, LLP
More by this Source
Ryan & Maniskas, LLP Announces Investigation of FedFirst Financial Corp.
Apr 21, 2014, 10:35 ET
Ryan & Maniskas, LLP Announces Investigation of Zygo Corporation
Apr 14, 2014, 10:58 ET
Ryan & Maniskas, LLP Announces Investigation of OBA Financial Services, Inc.
Apr 09, 2014, 10:34 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.